Ethanol Interactions With Dexmethylphenidate and Dl-Methylphenidate Spheroidal Oral Drug Absorption Systems in Healthy Volunteers

Overview

Journal J Clin Psychopharmacol

Specialty Pharmacology

Date 2017 Jun 8

PMID 28590363

Citations 8

Authors

Hao-Jie Zhu

Kennerly S Patrick

Arthur B Straughn

Owen T Reeves 3rd

Hilary Bernstein

Jian Shi

Heather J Johnson

Joshua M Knight

Aaron T Smith

Robert J Malcolm

John S Markowitz

Affiliations

Soon will be listed here.

Abstract

Background/purpose: Ethanol coadministered with immediate-release dl-methylphenidate (dl-MPH) or dexmethylphenidate (d-MPH) significantly increases the geomean maximum plasma concentration (Cmax) of d-MPH 22% and 15%, respectively, and elevates overall drug exposure and psychostimulant effects. We asked the question: Are these ethanol-MPH interactions based more fundamentally on (1) inhibition of postabsorption d-MPH metabolism or (2) acceleration of MPH formulation gastric dissolution by ethanol in the stomach? This was investigated using the pulsatile, distinctly biphasic, spheroidal oral drug absorption systems of dl-MPH and d-MPH.

Methods: In a randomized, 4-way crossover study, 14 healthy subjects received pulsatile dl-MPH (40 mg) or d-MPH (20 mg), with or without ethanol (0.6 g/kg), dosed 4 hours later. These 4 hours allowed the delayed-release second MPH pulse to reach a more distal region of the gut to preclude gastric biopharmaceutical influences. Plasma was analyzed using a highly sensitive chiral method. Subjective/physiological effects were recorded.

Findings/results: Ethanol increased the second pulse of d-MPH Cmax for dl-MPH by 35% (P < 0.01) and the partial area under the plasma concentration curve from 4 to 8 hours by 25% (P < 0.05). The respective values for enantiopure d-MPH were 27% (P = 0.001) and 20% (P < 0.01). The carboxylesterase 1-mediated transesterification metabolite ethylphenidate served as a biomarker for coexposure. Ethanol significantly potentiated stimulant responses to either formulation.

Implications/conclusions: These findings support drug dispositional interactions between ethanol and MPH as dominant over potential biopharmaceutical considerations. Understanding the pharmacology underlying the frequent coabuse of MPH-ethanol provides rational guidance in the selection of first-line pharmacotherapy for comorbid attention-deficit/hyperactivity disorder-alcohol use disorder.

Citing Articles

Regulation of Human Hydrolases and Its Implications in Pharmacokinetics and Pharmacodynamics.

Jung S, Zhu H Drug Metab Dispos. 2024; 52(11):1139-1151.

PMID: 38777597 PMC: 11495669. DOI: 10.1124/dmd.123.001609.

Regulation of carboxylesterases and its impact on pharmacokinetics and pharmacodynamics: an up-to-date review.

Liu Y, Li J, Zhu H Expert Opin Drug Metab Toxicol. 2024; 20(5):377-397.

PMID: 38706437 PMC: 11151177. DOI: 10.1080/17425255.2024.2348491.

Prediction of Carboxylesterase 1-mediated In Vivo Drug Interaction between Methylphenidate and Cannabinoids using Static and Physiologically Based Pharmacokinetic Models.

Qian Y, Markowitz J Drug Metab Dispos. 2022; 50(7):968-979.

PMID: 35512806 PMC: 11022897. DOI: 10.1124/dmd.121.000823.

Plasma Carboxylesterase 1 Predicts Methylphenidate Exposure: A Proof-of-Concept Study Using Plasma Protein Biomarker for Hepatic Drug Metabolism.

Shi J, Xiao J, Wang X, Jung S, Bleske B, Markowitz J Clin Pharmacol Ther. 2021; 111(4):878-885.

PMID: 34743324 PMC: 9249567. DOI: 10.1002/cpt.2486.

Methylphenidate for attention-deficit/hyperactivity disorder in adults: a narrative review.

Jaeschke R, Sujkowska E, Sowa-Kucma M Psychopharmacology (Berl). 2021; 238(10):2667-2691.

PMID: 34436651 PMC: 8455398. DOI: 10.1007/s00213-021-05946-0.

References

Tuerck D, Maboudian M, Wang Y, Sedek G, Pommier F, Appel-Dingemanse S . Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man. Int J Clin Pharmacol Ther. 2008; 45(12):662-8. DOI: 10.5414/cpp45662. View

Szobot C, Bukstein O . Attention deficit hyperactivity disorder and substance use disorders. Child Adolesc Psychiatr Clin N Am. 2008; 17(2):309-23, viii. DOI: 10.1016/j.chc.2007.11.003. View

Srinivas N, Hubbard J, Korchinski E, Midha K . Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans. Pharm Res. 1993; 10(1):14-21. DOI: 10.1023/a:1018956526016. View

Parker R, Laizure S . The effect of ethanol on oral cocaine pharmacokinetics reveals an unrecognized class of ethanol-mediated drug interactions. Drug Metab Dispos. 2009; 38(2):317-22. PMC: 2812060. DOI: 10.1124/dmd.109.030056. View

Zhu H, Wang X, Gawronski B, Brinda B, Angiolillo D, Markowitz J . Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J Pharmacol Exp Ther. 2013; 344(3):665-72. DOI: 10.1124/jpet.112.201640. View

Markowitz J, Patrick K . Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter?. J Clin Psychopharmacol. 2008; 28(3 Suppl 2):S54-61. DOI: 10.1097/JCP.0b013e3181733560. View

Zhu H, Patrick K, Yuan H, Wang J, Donovan J, Devane C . Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet. 2008; 82(6):1241-8. PMC: 2427248. DOI: 10.1016/j.ajhg.2008.04.015. View

Barrett S, Pihl R . Oral methylphenidate-alcohol co-abuse. J Clin Psychopharmacol. 2002; 22(6):633-4. DOI: 10.1097/00004714-200212000-00020. View

Tang M, Mukundan M, Yang J, Charpentier N, LeCluyse E, Black C . Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther. 2006; 319(3):1467-76. DOI: 10.1124/jpet.106.110577. View

10.

Yoshihara H, Sato N, Sasaki Y, Uchima E, Inoue A, Matsumura T . Effect of alcohol ingestion on portal venous blood flow in healthy volunteers: comparison between the subjects with and without ALDH I isozyme. Alcohol. 1985; 2(3):463-8. DOI: 10.1016/0741-8329(85)90116-8. View

11.

Parker R, Hu Z, Meibohm B, Laizure S . Effects of alcohol on human carboxylesterase drug metabolism. Clin Pharmacokinet. 2014; 54(6):627-38. PMC: 4450114. DOI: 10.1007/s40262-014-0226-2. View

12.

Edwards A, Kendler K . Twin study of the relationship between adolescent attention-deficit/hyperactivity disorder and adult alcohol dependence. J Stud Alcohol Drugs. 2012; 73(2):185-94. PMC: 3281978. DOI: 10.15288/jsad.2012.73.185. View

13.

Kollins S, Rush C, Pazzaglia P, Ali J . Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Exp Clin Psychopharmacol. 1998; 6(4):367-74. DOI: 10.1037//1064-1297.6.4.367. View

14.

Novak S, Kroutil L, Williams R, Van Brunt D . The nonmedical use of prescription ADHD medications: results from a national Internet panel. Subst Abuse Treat Prev Policy. 2007; 2:32. PMC: 2211747. DOI: 10.1186/1747-597X-2-32. View

15.

Monti P, Miranda Jr R, Nixon K, Sher K, Swartzwelder H, Tapert S . Adolescence: booze, brains, and behavior. Alcohol Clin Exp Res. 2005; 29(2):207-20. DOI: 10.1097/01.alc.0000153551.11000.f3. View

16.

Patrick K, Straughn A, Jarvi E, Breese G, Meyer M . The absorption of sustained-release methylphenidate formulations compared to an immediate-release formulation. Biopharm Drug Dispos. 1989; 10(2):165-71. DOI: 10.1002/bdd.2510100206. View

17.

Chai G, Governale L, McMahon A, Trinidad J, Staffa J, Murphy D . Trends of outpatient prescription drug utilization in US children, 2002-2010. Pediatrics. 2012; 130(1):23-31. DOI: 10.1542/peds.2011-2879. View

18.

Metzler C . Sample sizes for bioequivalence studies. Stat Med. 1991; 10(6):961-9; discussion 969-70. DOI: 10.1002/sim.4780100617. View

19.

Williard R, Middaugh L, Zhu H, Patrick K . Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity. Behav Pharmacol. 2007; 18(1):39-51. DOI: 10.1097/FBP.0b013e3280143226. View

20.

Patrick K, Gonzalez M, Straughn A, Markowitz J . New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Drug Deliv. 2005; 2(1):121-43. DOI: 10.1517/17425247.2.1.121. View